Lapatinib
- CAS No.
- 231277-92-2
- Chemical Name:
- Lapatinib
- Synonyms
- Tykerb;Tyverb;CS-220;GW-2016;CS-1860;GW 57201;Rapatini;lapatinib;GSK572016;GW-572016
- CBNumber:
- CB8855402
- Molecular Formula:
- C29H26ClFN4O4S
- Molecular Weight:
- 581.06
- MDL Number:
- MFCD09264194
- MOL File:
- 231277-92-2.mol
- MSDS File:
- SDS
- TDS File:
- TDS
| Product description | Number | Pack Size | Price |
| Lapatinib ≥98% (HPLC) | SML2259 | 10 mg | $69.6 |
| Lapatinib ≥98% (HPLC) | SML2259 | 50 mg | $283 |
| Lapatinib | L0360 | 250MG | $74 |
| Lapatinib | L0360 | 1G | $183 |
| Lapatinib ≥98% | 11493 | 5mg | $63 |
| More product size | |||
| Melting point | 144-146oC |
|---|---|
| Boiling point | 750.7±60.0 °C(Predicted) |
| Density | 1.381±0.06 g/cm3(Predicted) |
| storage temp. | 2-8°C(protect from light) |
| solubility | Soluble in DMSO (up to 200 mg/ml) |
| pka | 6.34±0.19(Predicted) |
| form | solid |
| color | Yellow |
| Stability | Stable for 2 years from date of purchase as supplied. Solutions in DMSO may be stored at -20°C for up to 1 month. |
| InChIKey | BCFGMOOMADDAQU-UHFFFAOYSA-N |
| SMILES | N1=C2C(C=C(C3=CC=C(CNCCS(C)(=O)=O)O3)C=C2)=C(NC2=CC=C(OCC3=CC=CC(F)=C3)C(Cl)=C2)N=C1 |
| CAS DataBase Reference | 231277-92-2(CAS DataBase Reference) |
| FDA UNII | 0VUA21238F |
| NCI Dictionary of Cancer Terms | GW572016; Tykerb |
| NCI Drug Dictionary | Tykerb |
| ATC code | L01EH01 |
| UNSPSC Code | 12352200 |
| NACRES | NA.77 |
SAFETY
Risk and Safety Statements
| Symbol(GHS) |  GHS07 |
|||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Signal word | Warning | |||||||||
| Hazard statements | H319-H362-H413 | |||||||||
| Precautionary statements | P201-P260-P263-P273-P305+P351+P338-P308+P313 | |||||||||
| WGK Germany | WGK 3 | |||||||||
| HS Code | 29349990 | |||||||||
| Storage Class | 11 - Combustible Solids | |||||||||
| Hazard Classifications | Aquatic Chronic 4 Eye Irrit. 2 Lact. |
|||||||||
| Hazardous Substances Data | 231277-92-2(Hazardous Substances Data) | |||||||||
| NFPA 704 |
|
Lapatinib price More Price(59)
| Manufacturer | Product number | Product description | CAS number | Packaging | Price | Updated | Buy |
|---|---|---|---|---|---|---|---|
| Sigma-Aldrich | SML2259 | Lapatinib ≥98% (HPLC) | 231277-92-2 | 10 mg | $69.6 | 2026-04-30 | Buy |
| Sigma-Aldrich | SML2259 | Lapatinib ≥98% (HPLC) | 231277-92-2 | 50 mg | $283 | 2026-04-30 | Buy |
| TCI Chemical | L0360 | Lapatinib | 231277-92-2 | 250MG | $74 | 2026-04-30 | Buy |
| TCI Chemical | L0360 | Lapatinib | 231277-92-2 | 1G | $183 | 2026-04-30 | Buy |
| Cayman Chemical | 11493 | Lapatinib ≥98% | 231277-92-2 | 5mg | $63 | 2026-04-30 | Buy |
Lapatinib Chemical Properties,Uses,Production
Indications and Usage
Lapatinib is a drug targeting breast cancer developed by British GlaxoSmithKline Co.
Human ErbB receptors belong to the type I tyrosine kinase (TK) receptor family, including ErbB1 (EGFR), ErbB2 (HER2), ErbB3 (HER3), and ErbB4 (HER4). The ErbB-1 (EGFR) and ErbB-2 (HER-2) receptors are often overexpressed or otherwise altered in cancer patients. Human epidermal growth factor receptor 2 (ErbB-2, HER-2) is known to be a human oncogene closely related with breast cancer. Its high expression in breast cancer often predicts lymph node metastasis and poor tumor differentiation, with poor prognosis. HER-2 is one of the target molecules for breast cancer-specific therapy. Lapatinib can act simultaneously on both Her-1 Her-2. The biological effects of this method inhibiting the proliferation and growth of tumor cells are much larger than only acting on one target. The combination of Lapatinib with Capecitabine is used to treat patients with advanced or metastatic breast cancer with overexpression of human epidermal receptor2, already treated with anthracyclines, paclitaxel, and trastuzumab. Clinical trials have shown that Lapatinib also effectively treats HER2-type cancer patients with Herceptin resistance.
Mechanisms of Action
Lapatinib is a tyrosine kinase inhibitor which can effectively inhibit the tyrosine kinase activity of human epidermal growth factor receptors 1 and 2 (ErbB1, ErbB2). It can uniquely act in a variety of ways, ensuring that breast cancer cells cannot receive growth signals. It inhibits intracellular EGFR (ErbB-1) and HER2 (ErbB-2) ATP sites, preventing tumor cell phosphorylation and activation, blocking down-regulation signals through the homogeneity and heterogeneity of EGFR (ErbB-1) and HER2 (ErbB-1) dimerization.
Binding Mode
Lapatinib is a type I1/2 inhibitor that binds to a DFG-in, αC helix-out inactive conformation of EGFR. The quinazoline N1 forms a hydrogen bond with the amide NH group of Met793 of the hinge. Although the aniline nitrogen is not involved in any direct hydrogen-bonding interactions with the protein, it serves to increase the basicity of quinazoline N1. The proximal methylsulfonylethylamino group, which functions to increase aqueous solubility of the drug, extends toward the solvent exposed region.
Description
Lapatinib, a new member of the 4-anilinoquinazoline class of RTK inhibitors
(RTKIs), was launched as an oral treatment for breast cancer.
Lapatinib has dual affinity for EGFR and HER2 tyrosine kinases. It is indicated
in combination with capecitabine for treating patients with advanced or
metastatic breast cancer whose tumors overexpress HER2 and who have
received prior therapy including an anthracycline, a taxane, and trastuzumab.
Previously marketed drugs from the 4-anilinoquinazoline class include
erlotinib (Tarceva) and gefitinib (IressaTM), both of which are indicated for
treating non-small-cell lung cancer (NSCLC). As with erlotinib and gefitinib, To Market, To Market 2007 475 lapatinib is an ATP-competitive kinase inhibitor. It inhibits the tyrosine kinase activity EGFR and HER-2 with apparent Ki values of 3 and 13 nM, respectively, and has slow off-rate kinetics (t1/2X300 min).
In addition, dividing the daily dose of lapatinib results in approximately 2-fold higher exposure at steady state compared to the same total dose administered once daily.
The chemical synthesis of lapatinib entails the condensation of 4-chloro-6-iodoquinazoline and 3-chloro-4-(3-fluorobenzyloxy)aniline to produce a diaryl amine intermediate followed by Stille coupling of the iodo group with 5-dioxolanyl-2-(tributylstannyl)furan and subsequent acid hydrolysis of the cyclic ketal to the corresponding aldehyde. Finally, reductive amination of the aldehyde intermediate with 2-(methanesulfonyl) ethylamine in the presence of sodium triacetoxyborohydride produces lapatinib.
.
Originator
GSK (US)
Uses
Lapatinib, used in the form of Lapatinib Ditosylate, is a potent EGFR and ErbB2 inhibitor with IC50 of 10.8 and 9.2 nM, respectively. It is a antineoplastic which is used in breast cancer research and a tyrosine kinase inhibitor. It is used for the treatment of patients with advanced or metastatic breast cancer whose tumors overexpress HER2 (ErbB2)
Definition
ChEBI: Lapatinib is an organofluorine compound, an organochlorine compound, a member of quinazolines and a member of furans. It has a role as an antineoplastic agent and a tyrosine kinase inhibitor. It is functionally related to a monofluorobenzene.
brand name
Tykerb
General Description
Class: receptor tyrosine kinase
Treatment: HER2-positive breast cancer
Elimination half-life = 24 h
Protein binding = 99%
Synthesis
A novel synthetic pathway for lapatinib is outlined below:
The synthetic route was used to produce 10 g of the final product lapatinib and the key intermediates. In summary, the overall synthesis route comprises of 6 reactions, performed in 5 steps, with an overall yield of 53.3%.
target
EGFR
storage
Store at -20°C
Background
Lapatinib is a dual inhibitor of EGFR and HER2 tyrosine kinases. Researchers have shown that lapatinib inhibits purified EGFR and HER2 tyrosine kinase domains in cell-free kinase assays with IC50 values of 10.8 nM and 9.2 nM, respectively, and HER4 with an IC50 of 367 nM. Lapatinib was greater than 300-fold more selective for HER2 and EGFR than many other kinases, including c-src, MEK, Erk, and p38 in these assays. Studies have shown that lapatinib effectively inhibits both EGFR and HER2 autophosphorylation in cell types over expressing these kinases, and cell growth inhibition is correlated with HER2 overexpression.
References
[1] EDGAR R WOOD. A unique structure for epidermal growth factor receptor bound to GW572016 (Lapatinib): relationships among protein conformation, inhibitor off-rate, and receptor activity in tumor cells.[J]. Cancer research, 2004, 64 18: 6652-6659. DOI:10.1158/0008-5472.can-04-1168
[2] BURRIS H A. Dual kinase inhibition in the treatment of breast cancer: initial experience with the EGFR/ErbB-2 inhibitor lapatinib.[J]. Oncologist, 2004, 9 Suppl 3: 10-15. DOI:10.1634/theoncologist.9-suppl\_3-10
[3] ISABEL CHU. The dual ErbB1/ErbB2 inhibitor, lapatinib (GW572016), cooperates with tamoxifen to inhibit both cell proliferation- and estrogen-dependent gene expression in antiestrogen-resistant breast cancer.[J]. Cancer research, 2005, 65 1: 18-25.
Lapatinib Preparation Products And Raw materials
Raw materials
Preparation Products
| Supplier | Tel | Country | ProdList | Advantage | |
|---|---|---|---|---|---|
| ZHEJIANG ESTCHEM CO.,LTD | 15957180504 | sales@zjestchem.com | China | 193 | 58 |
| SHANDONG BOYUAN PHARMACEUTICAL CO., LTD. | +86-531-88625728 +86-15806417970 | sales@boyuanpharm.com | China | 181 | 58 |
| Hebei Chuanghai Biotechnology Co., Ltd | +8615350571055 | Sibel@chuanghaibio.com | China | 8738 | 58 |
| Hebei Yanxi Chemical Co., Ltd. | +8618531123677 | faithe@yan-xi.com | China | 5853 | 58 |
| Henan Bao Enluo International TradeCo.，LTD | +86-17331933971 | deasea125996@gmail.com | China | 2472 | 58 |
| Hangzhou Hyper Chemicals Limited | +86-0086-57187702781 +8613675893055 | info@hyper-chem.com | China | 310 | 58 |
| Apeloa production Co.,Limited | +8619933239880 | admin@apcl.com.cn | China | 861 | 58 |
| BEIJING SJAR TECHNOLOGY DEVELOPMENT CO., LTD. | +86-18600796368 | sales@sjar-tech.com | China | 529 | 58 |
| Hebei Zhuanglai Chemical Trading Co Ltd | +86-16264648883 | niki@zlchemi.com | China | 7245 | 58 |
| Moxin Chemicals | +86-17320513646 +8617320513646 | anna@molcoo.com | China | 10000 | 58 |
Related articles
- Lapatinib: Uses and applications, ADME profiles and Side effect
- Lapatinib is an orally active dual tyrosine kinase inhibitor targeting both EGFR and HER2. Its ADME profiles and general infor....
- Sep 23，2025
- Synthesis and Bioactivity of Lapatinib
- Lapatinib is an oral tyrosine kinase inhibitor of small molecule epidermal growth factor (EGFR: ErbB-1, ErbB-2).
- Jul 19，2022
Related Qustion
Ask a questionView Lastest Price from Lapatinib manufacturers
| Image | Update time | Product | Price | Min. Order | Purity | Supply Ability | Manufacturer | |
|---|---|---|---|---|---|---|---|---|
 |
2026-05-02 | Lapatinib
231277-92-2
|
0.99 | RongNa Biotechnology Co.,Ltd | ||||
 |
2026-04-30 | Lapatinib
231277-92-2
|
US $0.00 / g | 1g | 98%min | 1000g | WUHAN FORTUNA CHEMICAL CO., LTD | |
 |
2026-04-30 | Lapatinib
231277-92-2
|
US $0.00 / g | 1g | More Than 99% | 100kg/Month | BEIJING SJAR TECHNOLOGY DEVELOPMENT CO., LTD. |
231277-92-2(Lapatinib)Related Search:
1of4
